Argus Initiates Coverage of DexCom (DXCM) with a Buy Rating
The firm told investors in a research note that it sees DexCom, Inc.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 3,822,085 | $333,629,802 | +261% | 0.38% |
| 2. | 236,063,000 | $232,007,079 | +79% | 0.79% | |
| 3. | D E Shaw D. E. Shaw | 1,961,590 | $171,227,191 | -37% | 0.12% |
| 4. | Citadel Investment Group Ken Griffin | 1,368,728 | $119,476,267 | -36% | 0.02% |
| 5. | 90,500,000 | $88,948,618 | -7% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.01 | 25,000 | $1,250,250.00 | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | $496,100.00 | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | $1,085,000.00 | 121,975 | 2013-03-11 | Filing | |
| $10.37 | 1,000 | $10,369.00 | 6,000 | 2012-03-08 | Filing | |
| $10.34 | 1,000 | $10,340.00 | 5,000 | 2012-03-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $80.29 | 500 | $40,145.00 | 94,102 | 2025-08-15 | Filing | |
| $81.54 | 195 | $15,900.30 | 51,121 | 2025-08-15 | Filing | |
| $81.02 | 2,555 | $207,002.52 | 51,316 | 2025-08-15 | Filing | |
| $88.99 | 1,466 | $130,459.34 | 106,689 | 2025-07-28 | Filing | |
| $86.03 | 8 | $688.24 | 53,871 | 2025-07-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 48,322,405 | $4,218,062,732 | 0.07% | |
| 2. | 39,032,096 | $3,407,111,662 | 0.06% | |
| 3. | 16,858,078 | $1,471,541,629 | 0.06% | |
| 4. | 16,705,195 | $1,458,196,471 | 1.09% | |
| 5. | 11,517,546 | $1,005,366,575 | 0.6% |
News See All
10 Best Strong Buy Growth Stocks to Buy Now
On August 27, Komal Sri-Kumar, Sri-Kumar Global Strategies president, appeared on CNBC’s ‘Squawk Box’ to talk about the fallout from President Trump’s firing of Fed Governor Lisa Cook, the effects...
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change
DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to close at $76.25 apiece as investors turned cautious following the announcement of a leadership change after the company’s strong...
DexCom, Inc. (NASDAQ:DXCM) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the DexCom Second Quarter 2025 Earnings Release Conference Call. My name is Abby, and I'll be your conference operator today.
Mizuho Lifts PT on DexCom (DXCM) to $100 From $95, Keeps an Outperform Rating
DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy healthcare stocks to buy now. On July 16, Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom, Inc.
10 Best Strong Buy Healthcare Stocks to Buy Now
On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC's 'The Exchange' to talk about whether any opportunity plays exist within the healthcare sector, and what pains the sector...
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push
DexCom, Inc. (NASDAQ:DXCM) ranks among the best fundamental stocks to buy according to hedge funds. Oppenheimer reaffirmed its $95 price target and Outperform rating for DexCom, Inc.
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating
DexCom, a global leader in glucose biosensing systems, stands out for its innovative continuous glucose monitoring (CGM) technology.
Billionaire Ken Griffin's 10 Midcap Stock Picks with Huge Upside Potential
Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.
Billionaire Hedge Funds
